Huntington's Disease (Rare) — Deal Benchmarks & Valuation
Market Analysis
Huntington's Disease (Rare) is one of the most actively transacted indications in rare disease licensing. Phase 1 deals for huntington's disease (rare) carry a median total deal value of $1.3B, with upfront payments ranging from $55M to $232M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Milestone structures for huntington's disease (rare) deals allocate $395M to development milestones, $305M to regulatory milestones, and $429M to commercial milestones. Royalty rates range from 5.8% to 11.6% at the base tier, with tiered escalation reaching 9.8%-15.6% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for huntington's disease (rare) licensing?
What royalty rates are standard for huntington's disease (rare) deals?
How are huntington's disease (rare) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.